Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Horvath

Showing results (171-180 of 279) with videos related to

Pageof 28
Sort By:
Acta Oncologica (Stockholm, Sweden)|January 1, 1996
Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer--ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study GroupC Tropé, H Andersson, E Björkholm, et al.
Investigational New Drugs|May 17, 2018
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancersAflah Roohullah, Adam Cooper, Anna J Lomax, et al.
The Prostate|October 7, 2014
INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survivalNatalie K Rynkiewicz, Clare G Fedele, Karen Chiam, et al.
Molecular & Cellular Proteomics : MCP|April 11, 2018
Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor ExplantsElizabeth V Nguyen, Margaret M Centenera, Max Moldovan, et al.
Clinical and Translational Medicine|September 30, 2022
Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortalityRuth Pidsley, Dilys Lam, Wenjia Qu, et al.
The Prostate|July 11, 2008
Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancerLye Lin Ho, James G Kench, David J Handelsman, et al.
Prostate Cancer and Prostatic Diseases|May 5, 2023
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancerTahlia Scheinberg, Hui-Ming Lin, Michael Fitzpatrick, et al.
JCO Precision Oncology|May 1, 2024
Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral NeuropathyNicole Yeung, Tiffany Li, Hui-Ming Lin, et al.
The Journal of Clinical Investigation|September 17, 2024
Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritanceNima Sharifi, Robert Diaz, Hui-Ming Lin, et al.
Pathology|July 1, 2011
Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimensJames G Kench, David R Clouston, Warick Delprado, et al.
Pageof 28

Showing results (171-180 of 279) with videos related to

Sort By:
Pageof 28
Acta Oncologica (Stockholm, Sweden)|January 1, 1996
Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer--ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study GroupC Tropé, H Andersson, E Björkholm, et al.
Investigational New Drugs|May 17, 2018
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancersAflah Roohullah, Adam Cooper, Anna J Lomax, et al.
The Prostate|October 7, 2014
INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survivalNatalie K Rynkiewicz, Clare G Fedele, Karen Chiam, et al.
Molecular & Cellular Proteomics : MCP|April 11, 2018
Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor ExplantsElizabeth V Nguyen, Margaret M Centenera, Max Moldovan, et al.
Clinical and Translational Medicine|September 30, 2022
Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortalityRuth Pidsley, Dilys Lam, Wenjia Qu, et al.
The Prostate|July 11, 2008
Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancerLye Lin Ho, James G Kench, David J Handelsman, et al.
Prostate Cancer and Prostatic Diseases|May 5, 2023
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancerTahlia Scheinberg, Hui-Ming Lin, Michael Fitzpatrick, et al.
JCO Precision Oncology|May 1, 2024
Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral NeuropathyNicole Yeung, Tiffany Li, Hui-Ming Lin, et al.
The Journal of Clinical Investigation|September 17, 2024
Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritanceNima Sharifi, Robert Diaz, Hui-Ming Lin, et al.
Pathology|July 1, 2011
Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimensJames G Kench, David R Clouston, Warick Delprado, et al.
Pageof 28